These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6506021)

  • 1. Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with factor Xa and thrombin.
    Handeland GF; Abildgaard U
    Thromb Res; 1984 Sep; 35(6):627-36. PubMed ID: 6506021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods.
    Houbouyan L; Padilla A; Gray E; Longstaff C; Barrowcliffe TW
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):24-30. PubMed ID: 8845459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay.
    Abildgaard U; Norrheim L; Larsen AE; Nesvold A; Sandset PM; Odegaard OR
    Haemostasis; 1990; 20(4):193-203. PubMed ID: 2173672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated determination of heparin with chromogenic substrates.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):184-94. PubMed ID: 6735276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplified assay for antithrombin III activity using chromogenic peptide substrate. Manual and automated method.
    Frantzen Handeland G; Abildgaard U; Aasen AO
    Scand J Haematol; 1983 Nov; 31(5):427-36. PubMed ID: 6648356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma.
    Abildgaard U; Larsen ML
    Thromb Res; 1984 Aug; 35(3):257-66. PubMed ID: 6547786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serine protease specificity for peptide chromogenic substrates.
    Mattler LE; Bang NU
    Thromb Haemost; 1977 Dec; 38(4):776-92. PubMed ID: 146272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
    Brooks MB
    Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
    Padilla A; Gray E; Pepper DS; Barrowcliffe TW
    Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of low molecular-weight heparin in hemodialysis patients].
    Schrader J; Rieger J; Müschen H; Stibbe W; Köstering H; Kramer P; Scheler F
    Klin Wochenschr; 1985 Jan; 63(2):49-55. PubMed ID: 3981950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methods.
    Svendsen LG; Fareed J; Walenga JM; Hoppensteadt D
    Semin Thromb Hemost; 1983 Oct; 9(4):250-62. PubMed ID: 6658459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.
    Koller M; Schoch U; Buchmann P; Largiadèr F; von Felten A; Frick PG
    Thromb Haemost; 1986 Dec; 56(3):243-6. PubMed ID: 3551180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin in hemodialysis and hemofiltration patients.
    Schrader J; Valentin R; Tönnis HJ; Hildebrand U; Stibbe W; Armstrong VW; Kandt M; Köstering H; Quellhorst E
    Kidney Int; 1985 Nov; 28(5):823-9. PubMed ID: 3936965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.
    Harenberg J; Giese C; Knödler A; Zimmermann R
    Haemostasis; 1989; 19(1):13-20. PubMed ID: 2537786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.